Science

Elvina Almuradova: Longer duration of ICI therapy linked to higher complete response rates in MMRd cancers

Elvina Almuradova/LinkedIn

Mar 15, 2025, 08:34

Elvina Almuradova: Longer duration of ICI therapy linked to higher complete response rates in MMRd cancers

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn about a paper published in NEJM:

“Longer Duration of ICI Therapy Linked to Higher Complete Response Rates in MMRd Cancers!

A systematic review published in NEJM Group found that longer neoadjuvant treatment with immune checkpoint inhibitors (ICIs) is associated with higher complete response rates in patients with mismatch repair-deficient (MMRd) cancers.

Anti-PD1 therapy alone for MMRd colorectal cancer (1–7 months): Complete response ranged from 0% to 100%
Anti-PD1 + anti-CTLA4 (shorter duration to reduce toxicity): 68% CR (4 weeks) – 80% CR (6 weeks)
Longer treatment is expected to improve tumour ablation rates.”

“The Duration of Immunotherapy for Mismatch Repair-Deficient Cancers”

Elvina Almuradova: Longer duration of ICI therapy linked to higher complete response rates in MMRd cancers

M0re posts featuring Elvina Almuradova.

cancer Elvina Almuradova ICI Therapy Immune Checkpoint Inhibitors mismatch repair deficient cancers MMRd MMRd colorectal cancer NEJM OncoDaily Oncology

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer